PT1417231E - Linfopoietina estromal tímica humana modificada - Google Patents

Linfopoietina estromal tímica humana modificada Download PDF

Info

Publication number
PT1417231E
PT1417231E PT2793761T PT02793761T PT1417231E PT 1417231 E PT1417231 E PT 1417231E PT 2793761 T PT2793761 T PT 2793761T PT 02793761 T PT02793761 T PT 02793761T PT 1417231 E PT1417231 E PT 1417231E
Authority
PT
Portugal
Prior art keywords
tslp
polypeptide
leu
activity
seq
Prior art date
Application number
PT2793761T
Other languages
English (en)
Portuguese (pt)
Inventor
Stewart D Lyman
Kirk P Van Ness
Raymond J Paxton
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of PT1417231E publication Critical patent/PT1417231E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT2793761T 2001-07-23 2002-07-23 Linfopoietina estromal tímica humana modificada PT1417231E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30734501P 2001-07-23 2001-07-23

Publications (1)

Publication Number Publication Date
PT1417231E true PT1417231E (pt) 2013-07-29

Family

ID=23189325

Family Applications (1)

Application Number Title Priority Date Filing Date
PT2793761T PT1417231E (pt) 2001-07-23 2002-07-23 Linfopoietina estromal tímica humana modificada

Country Status (11)

Country Link
US (9) US7288633B2 (cg-RX-API-DMAC7.html)
EP (1) EP1417231B1 (cg-RX-API-DMAC7.html)
JP (2) JP5329016B2 (cg-RX-API-DMAC7.html)
AU (1) AU2002359238B2 (cg-RX-API-DMAC7.html)
CA (1) CA2454578C (cg-RX-API-DMAC7.html)
DK (1) DK1417231T3 (cg-RX-API-DMAC7.html)
ES (1) ES2422879T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04000631A (cg-RX-API-DMAC7.html)
PL (1) PL371773A1 (cg-RX-API-DMAC7.html)
PT (1) PT1417231E (cg-RX-API-DMAC7.html)
WO (1) WO2003032898A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
ES2384960T3 (es) * 2001-12-18 2012-07-16 Cancer Research Technology Limited Procedimiento para la generación de líneas celulares proliferativas y que se diferencian
EP1651247B1 (en) * 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
DK2197903T3 (en) * 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
US11001624B2 (en) 2016-04-05 2021-05-11 Vib Vzw TSLP inhibitors
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
CA2118119C (en) 1992-04-30 2001-07-31 Robert C. Thompson Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
GB9209874D0 (en) 1992-05-07 1992-06-24 Ml Lab Plc Pharmaceutical compositions
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
CA2349762C (en) 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US7964713B2 (en) 2000-06-28 2011-06-21 Amgen Inc. Nucleic acid molecules encoding thymic stromal lympopoietin receptor proteins and a process for producing the encoded polypeptides thereof
WO2002000723A2 (en) 2000-06-28 2002-01-03 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
GB2381685A (en) 2001-10-30 2003-05-07 Amino Holdings Ltd Gateway device for converting digital signals to analogue signals
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
MXPA05002514A (es) 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
EP1651247B1 (en) 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
CA2577631A1 (en) 2004-08-20 2006-03-02 Amgen Inc. Methods and compositions for treating allergic inflammation
AU2007230868B2 (en) 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
KR20100034015A (ko) 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물

Also Published As

Publication number Publication date
US8598318B2 (en) 2013-12-03
PL371773A1 (en) 2005-06-27
US7973151B2 (en) 2011-07-05
US20160377630A1 (en) 2016-12-29
JP5329016B2 (ja) 2013-10-30
US7288633B2 (en) 2007-10-30
US7709217B2 (en) 2010-05-04
US20130023647A1 (en) 2013-01-24
US20150252089A1 (en) 2015-09-10
US20080145866A1 (en) 2008-06-19
EP1417231A4 (en) 2004-12-15
US9045558B2 (en) 2015-06-02
WO2003032898A3 (en) 2003-08-14
US20070218523A1 (en) 2007-09-20
DK1417231T3 (da) 2013-07-22
CA2454578C (en) 2013-06-25
AU2002359238B2 (en) 2008-01-17
US20210102955A1 (en) 2021-04-08
EP1417231A2 (en) 2004-05-12
ES2422879T3 (es) 2013-09-16
JP2005505293A (ja) 2005-02-24
CA2454578A1 (en) 2003-04-24
WO2003032898A2 (en) 2003-04-24
US20100167393A1 (en) 2010-07-01
JP2010279365A (ja) 2010-12-16
US20110230637A1 (en) 2011-09-22
EP1417231B1 (en) 2013-06-19
MXPA04000631A (es) 2004-06-25
US20140093956A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
US8598318B2 (en) Modified human thymic stromal lymphopoietin
ES2288036T5 (es) ADN de TSLP humano y polipéptidos
ES2210354T3 (es) Factor de necrosis tumoral humano delta y epsilon.
PT772624E (pt) Interleucina-15
KR20170030646A (ko) 인터류킨-2/인터류킨-2 수용체 알파 융합 단백질 및 사용 방법
JP2010187691A (ja) 哺乳類のトランスフォーミング増殖因子β−9
JP2010187698A (ja) 哺乳類のサイトカイン様ポリペプチド−10
AU2002359238A1 (en) Modified human thymic stromal lymphopoietin
JPH10511266A (ja) ヒト・インターロイキン−11受容体
ES2298106T3 (es) Proteinas de fusion que comprenden dos moleculas gp130 solubles.
US20090010872A1 (en) Chimeric soluble hyper il-11 and use thereof
AU620925B2 (en) New derivatives of human/bovine basic fibroblast growth factor
ES2211876T3 (es) Deteccion y tratamiento de mutaciones en un gel del ligando de cd40.
WO1996022370A1 (en) Human fas gene promoter region
JPH09512165A (ja) インターロイキン15
ES2244456T3 (es) Anticuerpos monoclonales selectivos para vgf y su uso para tratar trastornos relacionados con vgf.
JP3689111B2 (ja) インターロイキン15
ES2252032T3 (es) Modulacion de angiogenesis usando angiotensina-7 antiangiogenica y polinucleotidos codificantes para dicha sustancia para el tratamiento de tumores.
WO2001000664A2 (en) Secreted alpha-helical protein-36
JPH06228194A (ja) 可溶性キットリガンド
JP2010508856A (ja) トランスフォーミング増殖因子β−9の変異体及びその使用方法
HK1170933A1 (en) Method of producing recombinant tat-hoxb4h protein for use as a stimulant of hematopoiesis in vivo